Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Molecular Devices Becomes Global Distributor of IonFlux

Published: Tuesday, May 28, 2013
Last Updated: Tuesday, May 28, 2013
Bookmark and Share
Molecular Devices makes deal with Fluxion Biosciences to distribute their automated electrophysiology systems and associated products.

Molecular Devices® announced it has made an agreement with Fluxion Biosciences to become global distributor for the IonFlux™ portfolio of instrumentation and consumables. Molecular Devices will also provide support for all IonFlux Systems users through its recently expanded team of Application Specialists.

The IonFlux Systems offer an unrivalled level of simplicity for electrophysiology. Combined with low running costs, this makes the systems an ideal solution for laboratories in both academic and industrial settings. The IonFlux 16 Electrophysiology System is capable of delivering results from up to 64 test compounds per run, while the IonFlux HT Platform can deliver results from up to 256 test compounds per run.

Jeff Jensen, CEO of Fluxion, commented: “Molecular Devices’ long history in the electrophysiology field, combined with the expertise of its applications support team, means that they are ideally placed to support scientists working with IonFlux Systems. We are delighted that they will be taking responsibility for distributing the line worldwide.”

Kevin Chance, President of Molecular Devices, said: “The IonFlux Systems are an excellent complement to our existing line of electrophysiology products, which includes IonWorks Barracuda® and IonWorks Quattro™ Automated Systems with Population Patch Clamp™ Technology, PatchXpress® 7000A and the Axon® line of Conventional Electrophysiology Systems. The simplicity of the IonFlux Systems enables a broad range of scientists to access electrophysiology and ion channel research, making them a great addition to the Molecular Devices offering.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Molecular Devices Partners with Roche
Partnership will develop custom Ruthenium Nano-TRF Detection Platform.
Thursday, November 06, 2014
Molecular Devices Forms Scientific Advisory Board
Multidisciplinary team will guide product and application development to deliver maximum value to customers.
Thursday, December 27, 2012
Molecular Devices to attend ADME & Predictive Toxicology Europe
Company is to showcase its SpectraMax® Paradigm® microplate reader during the European conference in Munich, Germany, 13-14 March 2012.
Wednesday, February 29, 2012
Molecular Devices Awarded Patent for Population Patch Clamp Recording Technique
The parallel recording technique measures ionic currents from a population of cells, rather than single cells, on planar patch clamp systems and enhances ion channel assay success rates to near 100%.
Tuesday, January 10, 2012
Registration opens for RNAi and High Content Imaging 2011
Molecular Devices Inc. announces that they have opened registration for its RNAi & High Content Imaging Symposium 2011, to be held at the Oxford Spires Four Pillars, Oxford on 1st April 2011.
Tuesday, February 08, 2011
Molecular Devices Launches New Products & Customer-Focused Brand at Society for Biomolecular Sciences Meeting
New IonWorks Barracuda™ Automated High-Speed Patch Clamp System & AquaMax® 2000/4000 Microplate Washer 96 Cell-Wash Head
Thursday, April 08, 2010
Scientific News
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
Electrical Control of Cancer Cells
Research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) has revealed a new electrical mechanism that can control these switches.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
Structural Discoveries Could Aid in Better Drug Design
Scientists have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output.
Determining the Age of Fingerprints
Watch the imprint of a tire track in soft mud, and it will slowly blur, the ridges of the pattern gradually flowing into the valleys. Researchers have tested the theory that a similar effect could be used to give forensic scientists a way to date fingerprints.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!